Dose, Subgroup (n at final visit) | Physical ComponentSummary | Mental ComponentSummary | Mental HealthDomain |
---|---|---|---|
Elderly | |||
1 mg, with psychiatric disorders (n = 37)a | |||
Baseline | 40.9 (15.9) | 43.6 (9.9) | 39.5 (12.2) |
Final visit (LOCF) | 42.4 (12.2) | 50.8 (10.9) | 47.3 (11.2) |
Change from baseline | 1.5 (10.4) | 6.8 (11.2)* | 7.3 (12.0)* |
2 mg, with psychiatric disorders (n = 42) | |||
Baseline | 41.1 (15.7) | 44.7 (10.6) | 41.5 (13.2) |
Final visit (LOCF) | 43.3 (12.4) | 50.5 (9.0) | 47.0 (11.3) |
Change from baseline | 2.3 (10.6) | 5.8 (8.4)* | 5.5 (8.8)* |
1 mg, without psychiatric disorders (n = 42) | |||
Baseline | 46.8 (10.3) | 54.7 (7.2) | 53.7 (8.7) |
Final visit (LOCF) | 48.4 (7.4) | 57.5 (6.8) | 57.0 (7.2) |
Change from baseline | 1.6 (7.0) | 2.9 (7.2)† | 3.3 (8.2)† |
2 mg, without psychiatric disorders (n = 41) | |||
Baseline | 51.7 (5.0) | 55.3 (7.9) | 54.6 (7.7) |
Final visit (LOCF) | 51.5 (6.2) | 56.1 (7.4) | 55.7 (7.0) |
Change from baseline | −0.2 (5.3) | 0.8 (7.5) | 1.1 (8.7) |
Nonelderly | |||
2 mg, with psychiatric disorders (n = 43) | |||
Baseline | 47.1 (10.4) | 38.3 (8.7) | 37.7 (9.1) |
Final visit (LOCF) | 47.5 (9.8) | 44.6 (9.7) | 43.6 (10.1) |
Change from baseline | 0.4 (10.5) | 6.3 (9.3)* | 5.9 (9.8)* |
3 mg, with psychiatric disorders (n = 36)a | |||
Baseline | 49.4 (8.8) | 39.8 (8.2) | 39.5 (6.9) |
Final visit (LOCF) | 49.5 (11.0) | 44.2 (8.3) | 44.4 (10.1) |
Change from baseline | −0.1 (8.9) | 4.3 (9.2)‡ | 4.8 (11.3)† |
2 mg, without psychiatric disorders (n = 41) | |||
Baseline | 50.6 (8.0) | 49.8 (7.6) | 50.1 (9.1) |
Final visit (LOCF) | 51.7 (9.7) | 50.8 (9.2) | 50.7 (10.5) |
Change from baseline | 1.2 (8.6) | 1.0 (9.6) | 0.7 (12.0) |
3 mg, without psychiatric disorders (n = 39)a | |||
Baseline | 50.9 (11.4) | 49.4 (7.9) | 50.4 (7.8) |
Final visit (LOCF) | 52.5 (8.1) | 51.2 (8.1) | 51.9 (7.8) |
Change from baseline | 1.7 (10.8) | 1.7 (5.9) | 1.6 (7.3) |